Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.65 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.57 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292458 | 1.00 | PAM (0.65) | PAMNFE2L2PIN1PTGS1PTGS2 | |
| SCHEMBL23832889 | 0.82 | PAM (0.57) | PAMPIN1PTGS1PTGS2MAOB | |
| SCHEMBL1207193 | 0.81 | TBXAS1 (0.52) | NFE2L2PIN1PTGS1PTGS2NQO2 | |
| SCHEMBL1207196 | 0.81 | TBXAS1 (0.52) | NFE2L2PIN1PTGS1PTGS2NQO2 | |
| SCHEMBL29166002 | 0.81 | PAM (0.67) | PAMFBP1MAOAMAOB | |
| SCHEMBL30817035 | 0.81 | PAM (0.67) | PAMFBP1MAOAMAOB | |
| SCHEMBL7612524 | 0.79 | PAM (0.65) | PAMCYP1B1MAOAMAOB | |
| SCHEMBL7612527 | 0.79 | PAM (0.65) | PAMCYP1B1MAOAMAOB | |
| SCHEMBL9294589 | 0.79 | PAM (0.65) | PAMFBP1 | |
| SCHEMBL582727 | 0.79 | PAM (1.00) | PAMCYP1B1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723105-B1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | LILLY CO ELI (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-1723105-B1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | LILLY CO ELI (US) | 2013-05-15 | — | — | EP | disclosed |
| US-7728150-B2 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728150-B2 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728150-B2 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-08-09 | — | — | US | disclosed |
| WO-2007044796-A2 | PYRIDAZINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1723105-A1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005092854-A1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092854-A1 | BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| US-5607953-A | ANTIISCHEMIC AGENTS | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0344577-B1 | Butenoic or propenoic acid derivatives | EISAI CO LTD (JP) | 1996-10-09 | — | — | EP | disclosed |
| US-5382595-A | Antiischemic agents | EISAI CO., LTD. (JP) | 1995-01-17 | — | — | US | disclosed |
| US-5177089-A | Antiischemic agent, vasodilator | EISAI CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0344577-A2 | Butenoic or propenoic acid derivatives | Eisai Co., Ltd. (JP) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR1H2 | PAM 2130/4885NFE2L2 932/4885PIN1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.